Evolus, Inc. (NASDAQ:EOLS) Stake Decreased by Great Point Partners LLC

Great Point Partners LLC reduced its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 52.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,170,000 shares of the company’s stock after selling 1,281,772 shares during the period. Evolus makes up 5.6% of Great Point Partners LLC’s investment portfolio, making the stock its 4th biggest position. Great Point Partners LLC owned about 1.85% of Evolus worth $18,954,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EOLS. Assenagon Asset Management S.A. lifted its stake in Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after purchasing an additional 930,566 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Evolus by 24.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after buying an additional 35,760 shares during the last quarter. Armistice Capital LLC purchased a new stake in Evolus in the second quarter worth approximately $3,906,000. California State Teachers Retirement System boosted its stake in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after buying an additional 739 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Evolus by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Stock Performance

EOLS stock opened at $12.83 on Wednesday. The business has a 50 day moving average of $15.50 and a 200 day moving average of $13.86. Evolus, Inc. has a twelve month low of $9.29 and a twelve month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on EOLS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th.

Insider Transactions at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. The trade was a 6.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. The trade was a 2.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.